Medical treatment received by recruited patients with type 2 diabetes by region/country
| Country/region | On OAD treatment (%) | On insulin treatment (%) | With hypertension (%) | On antihypertensive treatment (%)* | With dyslipidemia (%) | On lipid-lowering treatment (%)† |
|---|---|---|---|---|---|---|
| Eurasia (n=1834) | 76 | 50 | 84 | 98 | 75 | 83 |
| Georgia (n=152) | 41 | 100 | 80 | 100 | 73 | 99 |
| Kazakhstan (n=413) | 84 | 40 | 83 | 98 | 71 | 89 |
| Russia (n=540) | 76 | 53 | 88 | 99 | 69 | 78 |
| Ukraine (n=353) | 83 | 42 | 81 | 98 | 77 | 72 |
| Uzbekistan (n=376) | 76 | 47 | 82 | 98 | 84 | 86 |
| Africa (n=2220)‡ | 83 | 38 | 57 | 98 | 47 | 84 |
| Algeria (n=514) | 92 | 42 | 69 | 99 | 56 | 92 |
| Cameroon (n=524) | 71 | 35 | 53 | 96 | 36 | 60 |
| Egypt (n=371) | 83 | 37 | 55 | 100 | 44 | 95 |
| Morocco (n=498) | 84 | 36 | 53 | 97 | 46 | 87 |
| Senegal (n=50) | 82 | 20 | 52 | 92 | 46 | 46 |
| Tunisia (n=313) | 85 | 43 | 56 | 99 | 53 | 90 |
| Middle East (n=2065) | 94 | 23 | 62 | 99 | 74 | 95 |
| Jordan (n=296) | 96 | 19 | 65 | 99 | 71 | 93 |
| KSA (n=199) | 93 | 32 | 54 | 100 | 68 | 99 |
| Lebanon (n=1059) | 93 | 23 | 61 | 98 | 72 | 94 |
| UAE (n=511) | 95 | 23 | 64 | 100 | 83 | 98 |
| South Asia (n=1195) | 93 | 33 | 61 | 98 | 54 | 94 |
| India (n=994) | 94 | 33 | 60 | 98 | 56 | 95 |
| Pakistan (n=201) | 89 | 31 | 61 | 98 | 45 | 89 |
| Turkey (n=842) | 81 | 46 | 63 | 98 | 56 | 86 |
*Among patients with hypertension.
†Among patients with dyslipidemia.
‡Owing to the small sample size (N=50), Senegal was not be included in Africa results in this table.
KSA, Kingdom of Saudi Arabia; OAD, oral antihyperglycemic drug; UAE,United Arab Emirates.